Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Costs and economics

Topic: Risk, prevention and care in population studies

Plain-language summary

Introduction The study aimed to estimate the utilization and lifetime costs of formal care for individuals with Alzheimer's disease (AD) dementia in Sweden. Methods We used longitudinal data from 20,366 individuals (mean age: 78.54 years) diagnosed with AD dementia from the Swedish Register of Cognitive/Dementia Disorders linked to other registers to derive data on formal care utilization, including inpatient and outpatient specialist care, prescribed drugs, and social care. We estimated formal care utilization across AD dementia stages defined by the Mini-Mental State Examination and the lifetime formal care costs (in 2023 Swedish krona, SEK) in patients with AD dementia using the Zhao and Tian estimator, which uses the inverse probability weighting technique to account for censoring due to loss to follow-up. The estimates of lifetime costs were compared with those of controls matched to patients with AD dementia by birth year, sex, and region of residence at the time of diagnosis. Results The number of outpatient specialist visits decreased as AD severity increased, while the number of drug prescriptions and social care utilization increased with advancing AD stages. The estimated lifetime costs of formal care for AD dementia were 2,440,000 SEK (€212,174; $US230,189; 95% CI 2,088,000-2,793,000 SEK), compared with 510,000 SEK (€44,348; $US48,113; 95% CI 482,000-539,000 SEK) for matched controls. Conclusions This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. These findings will provide inputs for future economic evaluations of treatments and preventive interventions for AD dementia.

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 20,366 participants. This register-based study estimated that lifetime formal care costs for people with Alzheimer's disease dementia in Sweden were about 2,440,000 SEK, compared with 510,000 SEK for matched controls, with drug prescriptions and social care use rising as disease severity increased. Reported effect size: Lifetime formal-care cost 2,440,000 SEK vs 510,000 SEK for matched controls.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Xia, X., Eriksdotter, M., Clark, A., Brogaard, N. J., Gundgaard, J., Polavieja, P., et al. (2026). Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01612-5

Vancouver

Xia X, Eriksdotter M, Clark A, Brogaard NJ, Gundgaard J, Polavieja P, et al. Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01612-5. PMID: 41920501.

BibTeX

@article{xia2026-41920501,
  author  = {Xia, X. and Eriksdotter, M. and Clark, A. and Brogaard, N. J. and Gundgaard, J. and Polavieja, P. and Skajaa, N. and Zetterberg, H. and Kern, S. and Skillbäck, T. B. and Jönsson, L.},
  title   = {{Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden}},
  journal = {PharmacoEconomics},
  year    = {2026},
  doi     = {10.1007/s40273-026-01612-5},
  pmid    = {41920501},
  url     = {https://doi.org/10.1007/s40273-026-01612-5}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 11 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This register-based study estimated that lifetime formal care costs for people with Alzheimer's disease dementia in Sweden were about 2,440,000 SEK, compared with 510,000 SEK for matched controls, with drug prescriptions and social care use rising as disease severity increased. It describes the cost of care over the disease course and does not test any treatment, cure or prevention.

Study details

Limitations

Primary care visits were not included owing to lack of data, likely underestimating costs; the eight-year window may not capture the full interval from diagnosis to death; truncating controls' follow-up to match cases may have overestimated the cost difference; the MCI stage was not considered because of insufficient data.

How this study scored 56/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 55 of the 98 points it could be judged on, which is 56 of 100. Total 56 of 100.55 of the 98 points we could judge = 56 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 55 of the 98 points we could judge it on, which is 56 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (PharmacoEconomics)
Journal's citation record 2 / 4 PharmacoEconomics: journal h-index 153 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 4 / 4 20,366 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Linus Jönsson: h-index 55 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 11 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41920501)
Free to read — / 2 Access not recorded — left out of this score
Points 55 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 98 points we could judge it on is 56 out of 100.
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Costs and economics from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Costs and economics

See all studies in Costs and economics →